Nicholas Duesbery PhD

Nicholas Duesbery PhD

Assistant VP of Research

I provideoversight for all industry-sponsored and investigator-initiated oncologyclinical research at Ochsner. I also oversee Ochsner’s Biorepository and theOchsner Center for Outcomes Research. Before I transitioned to anadministrative position, I was the head of the Laboratory for Cancer andDevelopmental Cell Biology at Van Andel Research Institute in Grand Rapids, Mi.My research interests focused on MEK signaling in health and disease.

EDUCATION/TRAINING (Beginwith baccalaureate or other initial professional education, such as nursing,include postdoctoral training and residency training if applicable. Add/deleterows as necessary.)

 

Queen’s University,  Kingston, Ontario, Canada

BSc (Hons.)

05/1987

Biology

University  of Toronto, Toronto, Ontario, Canada

MSc

09/1990

Zoology/Dev.  Biology

University  of Toronto, Toronto, Ontario, Canada

PhD

03/1996

Zoology/Dev.  Biology

National  Cancer Institute, Post-Doctoral Fellowship, Frederick, Maryland, USA

 

03/1999

Molecular  Oncology

https://orcid.org/0000-0002-5708-4984

https://www.ncbi.nlm.nih.gov/myncbi/16gyk9zrtYSk9/bibliography/public/

SelectedPublications

Lee,C-S, Dykema, KJ, Hawkins, DM, Cherba, DM, Webb, CP, Furge, KA, and Duesbery,NS. 2011.  Mitogen-activated proteinkinase kinase 2 is sufficient but not necessary for proliferation andanchorage-independent growth of SK-MEL-28 melanoma cells.  PLoS One, 6(2): e17165. doi:10.1371/journal.pone.0017165.

Bromberg-White,JL, Boguslawski, EA, Hekman, D, Kort, EJ, and Duesbery, NS. 2011.  Persistent Inhibition of Oxygen-InducedRetinal Neovascularization by Anthrax Lethal Toxin.  I.O.V.S. 52(12), 8979-8992.

Ding,Y., E.A. Boguslawski, B.D. Berghuis, J.J. Young, Z. Zhang, K. Hardy, K. Furge,E. Kort, A.E. Frankel, R.V. Hay, J.H. Resau, and N.S. Duesbery.  2008. Mitogen-activated protein kinase kinase signaling promotes growth andvascularization of fibrosarcoma.  Mol.Cancer Ther. 7(3): 648–658.

Young,J.J., J.L. Bromberg-White, C. Zylstra, J.T. Church, E. Boguslawski, J.H. Resau,B.O. Williams, and N.S. Duesbery. 2007.  LRP5 and LRP6 are notrequired for protective antigen-mediated internalization or lethality ofanthrax lethal toxin.  PLoS Path. 3(3):e27.  PMC180872.

Abi-Habib,R.J., J.O. Urieto, S. Liu, S.H. Leppla, N.S. Duesbery, and A.E. Frankel.2005.  BRAF status and mitogen-activatedprotein/extracellular signal–regulated kinase kinase 1/2 activity indicatesensitivity of melanoma cells to anthrax lethal toxin.  Mol. Cancer Ther.  4(9): 1303–1310.

Liang,X., J.J. Young, S.A. Boone, D.S. Waugh, and N.S. Duesbery.  2004. Involvement of domain II in toxicity of anthrax lethal factor. J. Biol. Chem. 279(50): 52473–52478.

Chopra,A.P., X. Liang, S. Boone, and N.S. Duesbery. 2003.  Anthrax lethal factorproteolysis and inactivation of MAP-kinase-kinase.  J. Biol. Chem. 278(11): 9402–9406.

Koo,H.-M., M. VanBrocklin, M.J. McWilliams, S.H. Leppla, N.S. Duesbery, and G.F. VandeWoude.  2002.  Apoptosis and melanogenesis in human melanomacells induced by anthrax lethal factor inactivation of mitogen-activatedprotein kinase kinase.  Proc. Natl. Acad. Sci. U.S.A. 99(5):3052–3057.  PMC122471.

Duesbery,N.S., J. Resau, C.P. Webb, S. Koochekpour, H.-M. Koo, S.H. Leppla, and G.F.Vande Woude, G.F.  2001.  Suppression of ras-mediated transformationand inhibition of tumor growth and angiogenesis by anthrax lethal factor, aproteolytic inhibitor of multiple MEK pathways. Proc. Natl. Acad. Sci. U.S.A. 98(7): 4089–4094.  PMC31184.

Duesbery,N.S., C.P. Webb, S.H. Leppla, V.M. Gordon, K.R. Klimpel, T.D. Copeland, T.D.,N.G. Ahn, M. Oskarsson, K. Fukasawa, K.D. Paull, and G.F. Vande Woude.  1998. Proteolytic inactivation of MAP-kinase kinaseby anthrax lethal factor. Science 280(5364): 734–737.

https://research.ochsner.org/clinical-research

Keywords:Clinical Research, Outcomes Research, Biorepository, Oncology

LCRC Faculty

Missy Wooley
Population Sciences
Louisiana Tech University
Asim Abdel-Mageed DVM PhD
Therapeutics & Diagnostics
Tulane University School of Medicine
Ramsy Abdelghani, MD
Therapeutics & Diagnostics
Tulane University School of Medicine
Jiri Adamec, PhD
Therapeutics & Diagnostics
LSU Health - New Orleans
Suresh K. Alahari PhD
Therapeutics & Diagnostics
LSU Health - New Orleans
Ashad Alam, MD, PhD
Tumor Biology
Ochsner Health
Muralidharan Anbalagan, PhD
Therapeutics & Diagnostics
Tulane University School of Medicine
Wayne L. Backes PhD
Tumor Biology
LSU Health - New Orleans
Ambuga Badari, MD
Therapeutics & Diagnostics
Ochsner Health